|
 |
| home > epc > winter 2001 > arm for the pharmaceutical industry - protecting pharmaceutical brands and the impact of the internet |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
Intellectual property has always been vital to the pharmaceutical industry. The future earnings of new drugs are assessed on the basis that they will have very high profit margins because of their virtual monopoly on the market until the patent expires. But once the 20-year patent expires, pharmaceutical companies increasingly rely on their brands to sustain sales on their blockbusting drugs.
The growth of the Internet is further complicating this issue. Whilst it offers opportunities to develop brands in new ways online, it also harbours many dangers for companies, particularly in controversial industries such as pharmaceuticals.
Pharmaceutical companies have long held the view that patents equal profits. Their products require vast investment in research and development, as well as extensive and rigorous testing, before they reach the market. But, given the fact that once a drug is approved, a well-drafted patent gives a pharmaceutical company 20 years of uninterrupted monopoly in which to sell and market a drug, pharmaceutical giants have traditionally paid more attention to their patent portfolio than to their trade marks and brands. GlaxoSmithKline's ranitidine hydrochloride (Zantac) is a good case in point. Zantac is an anti-ulcer drug for which Glaxo obtained a patent. To get an idea of the potential value of the patent, this monopoly was worth approximately two to three million pounds in profits to Glaxo for every single day that it lasted.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
ICSE India
1-3 December 2010, Mumbai, India
ICSE is the international stage for companies providing outsourcing services in clinical trials, contract research, custom manufacturing, biotechnology, IT, analytical services, packaging services and logistics. The first ICSE India event was launched in 2007. For years ICSE has been connecting buyers and sellers in the market of (bio)pharmaceutical and pharma-related contract services. With a keen eye for new needs and new developments, each ICSE event is set up to fulfil its role as meeting place and intermediary as effectively as possible.
More info >> |
|
 |
News and Press Releases |
 |
ClinTec International
ClinTec International, a global Clinical Research Organisation (“CRO”) announces a financial and strategic partnership with Elephant Capital Plc., an AIM market listed private equity firm. With an investment of £8 Million GBP, Elephant has acquired a significant minority stake in ClinTec. Through this investment, Elephant has entered the attractive clinical research base, where ClinTec operates as a global provider of outsourcing solutions addressing the drug development lifecycle. Managing Partner of Elephant Capital LLP, Gaurav Burman, and Non-Executive Director of Elephant Capital Plc, James Hauslein, have also made personal co-investments in this transaction.
More info >> |
|
 |
